Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo - PubMed (original) (raw)
doi: 10.1124/jpet.103.064535. Epub 2004 Feb 11.
Robert J Schmidt, Patricia Foxworthy, Youyan Zhang, Jiannong Dai, William R Bensch, Raymond F Kauffman, Hong Gao, Timothy P Ryan, Xian-Cheng Jiang, Sotirios K Karathanasis, Patrick I Eacho, Guoqing Cao
Affiliations
- PMID: 14960661
- DOI: 10.1124/jpet.103.064535
Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo
Thomas P Beyer et al. J Pharmacol Exp Ther. 2004 Jun.
Abstract
Liver X receptors (LXRs) are master transcription factors regulating cholesterol and fatty acid metabolism. Treatment of C57B6 mice with a specific synthetic LXR agonist, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)-ethyl]phenyl]-benzenesulfonamide (T0901317), resulted in elevated high-density lipoprotein (HDL) cholesterol as well as plasma and liver triglycerides. Peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists are known to induce peroxisomal fatty acid beta-oxidation and also mediate HDL cholesterol metabolism. We have explored the hypothesis that simultaneous activation of PPARalpha and LXR may lead to additive effects on HDL cholesterol elevation as well as attenuation of triglyceride accumulation. Coadministration of T0901317 and the specific PPARalpha agonist [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy14643)] in mice led to synergistic elevation of HDL cholesterol that was primarily associated with enlarged HDL particles enriched with apoE and apoAI. Liver phospholipid transfer protein (PLTP) mRNA and plasma PLTP activity were additively elevated, suggesting a role of PLTP in the observed HDL cholesterol elevation. Moderate increases in plasma triglyceride levels induced by LXR activation was reduced, whereas the accumulation of triglyceride in the liver was not altered upon coadministration of the PPARalpha agonist. Peroxisomal fatty acid beta-oxidation in the liver was dramatically elevated upon PPARalpha activation as expected. Interestingly, activation of LXRs via T0901317 also led to a significant increase in peroxisomal fatty acid beta-oxidation. Sterol regulatory element binding protein 1c expression was dramatically up-regulated by the LXR agonist but was not changed with PPARalpha agonist treatment. Liver lipoprotein lipase expression was additively increased upon LXR agonist and PPARalpha agonist coadministration. Our studies mark the first exploration of nuclear receptor interplay on lipid homeostasis in vivo.
Similar articles
- Phospholipid transfer protein is regulated by liver X receptors in vivo.
Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC. Cao G, et al. J Biol Chem. 2002 Oct 18;277(42):39561-5. doi: 10.1074/jbc.M207187200. Epub 2002 Aug 9. J Biol Chem. 2002. PMID: 12177004 - Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Yatoh S, Kitamine T, Okazaki H, Tamura Y, Sekiya M, Takahashi A, Hasty AH, Sato R, Sone H, Osuga J, Ishibashi S, Yamada N. Yoshikawa T, et al. Mol Endocrinol. 2003 Jul;17(7):1240-54. doi: 10.1210/me.2002-0190. Epub 2003 May 1. Mol Endocrinol. 2003. PMID: 12730331 - Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Ide T, et al. Mol Endocrinol. 2003 Jul;17(7):1255-67. doi: 10.1210/me.2002-0191. Epub 2003 May 1. Mol Endocrinol. 2003. PMID: 12730332 - Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J. Bełtowski J. Cardiovasc Ther. 2008 Winter;26(4):297-316. doi: 10.1111/j.1755-5922.2008.00062.x. Cardiovasc Ther. 2008. PMID: 19035881 Review. - Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Wójcicka G, et al. Postepy Hig Med Dosw (Online). 2007 Dec 3;61:736-59. Postepy Hig Med Dosw (Online). 2007. PMID: 18063918 Review.
Cited by
- Liver X Receptor Ligand GAC0001E5 Downregulates Antioxidant Capacity and ERBB2/HER2 Expression in HER2-Positive Breast Cancer Cells.
Premaratne A, Basu S, Bagchi A, Zhou T, Feng Q, Lin CY. Premaratne A, et al. Cancers (Basel). 2024 Apr 25;16(9):1651. doi: 10.3390/cancers16091651. Cancers (Basel). 2024. PMID: 38730603 Free PMC article. - Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease.
Kim H, Park C, Kim TH. Kim H, et al. Cells. 2023 May 1;12(9):1292. doi: 10.3390/cells12091292. Cells. 2023. PMID: 37174692 Free PMC article. Review. - Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets.
Zhang W, Lv Z, Zhang Y, Gopinath SCB, Yuan Y, Huang D, Miao L. Zhang W, et al. Oxid Med Cell Longev. 2022 Sep 29;2022:6006601. doi: 10.1155/2022/6006601. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36211824 Free PMC article. Retracted. - Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression.
Haas MJ, Mooradian AD. Haas MJ, et al. Drugs. 2022 Jul;82(10):1055-1075. doi: 10.1007/s40265-022-01743-x. Epub 2022 Jul 21. Drugs. 2022. PMID: 35861923 Review. - Remembering your A, B, C's: Alzheimer's disease and ABCA1.
Lewandowski CT, Laham MS, Thatcher GRJ. Lewandowski CT, et al. Acta Pharm Sin B. 2022 Mar;12(3):995-1018. doi: 10.1016/j.apsb.2022.01.011. Epub 2022 Jan 24. Acta Pharm Sin B. 2022. PMID: 35530134 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous